%0 Journal Article
%A Afshar-Oromieh, Ali
%A Eiber, Matthias
%A Fendler, Wolfgang
%A Schmidt, Matthias
%A Rahbar, Kambiz
%A Ahmadzadehfar, Hojjat
%A Umutlu, Lale
%A Hadaschik, Boris
%A Hakenberg, Oliver W
%A Fornara, Paolo
%A Kurth, Jens
%A Neels, O.
%A Wester, Hans-Jürgen
%A Schwaiger, Markus
%A Kopka, Klaus
%A Haberkorn, Uwe
%A Herrmann, Ken
%A Krause, Bernd J
%T Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET/CT.[DGN-Handlungsempfehlung (S1-Leitlinie) – PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms – Stand: 01/2022 – AWMF-Registernummer: 031-055].
%J Nuklearmedizin
%V 62
%N 1
%@ 0029-5566
%C Stuttgart
%I Thieme
%M DKFZ-2023-00290
%P 5 - 19
%D 2023
%X PSMA-PET/CT for imaging prostate cancer (PC) has spread worldwide since its clinical introduction in 2011. The majority of experiences have been collected for PSMA-PET-imaging of recurrent PC. Data for primary staging of high-risk PC are highly promising. Meanwhile, a plethora of PSMA-ligands are available for clinical use (e. g. 68Ga-PSMA-11, 68Ga-PSMA-I</td><td width="150">
%X T, 68Ga-PSMA-617, 18F-DCFBC, 18F-DCFPyL, 18F-PSMA-1007, 18F-rhPSMA-7 and 18F-JK-PSMA-7). However, an official approval is available only for 68Ga-PSMA-11 (approved by the US FDA in 2020) and 18F-DCFPyL (approved by the US FDA in 2021).Recommendations for acquisition times vary from 1-2 h p. i. It has been shown that for the majority of tumour lesions, the contrast in PSMA-PET/CT increases with time. Therefore, additional late imaging can help to clarify unclear findings. PSMA-PET/CT should be performed prior to commencing an androgen deprivation therapy (ADT) since (long term) ADT reduces the visibility of PC lesions. Following injection of PSMA-ligands, hydration and forced diuresis are recommended for PSMA-ligands with primarily excretion via the kidneys in order to increase the visibility of tumour lesions adjacent to the urinary bladder.PSMA-ligands are physiologically taken up in multiple normal organs. For some 18F-labelled PSMA-ligands, presence of unspecific focal bone uptake has been reported. When using these tracers, focal bone uptake without CT-correlate should be interpreted with great caution. Besides prostate cancer, practically all solid tumors express PSMA in their neovasculature thereby taking up PSMA-ligands, although usually at a lower extent compared to PC. Also multiple benign lesions and inflammatory processes (e. g. lymph nodes) take up PSMA-ligands, also usually at lower extent compared to PC.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36746147
%R 10.1055/a-1984-8167
%U https://inrepo02.dkfz.de/record/265695